UNITED STATES | January 27, 2026 — ABANZA, a medical technology company focused on advancing soft-tissue fixation solutions, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for QuadLock™, a knotless, bidirectional, tension-adjustable fixation system designed for anterior cruciate ligament (ACL) reconstruction. The clearance marks a significant regulatory milestone, enabling U.S. commercialization of a device engineered to provide precise graft tension control and enhanced fixation stability across multiple commonly used ACL graft configurations.
Science Significance
From a scientific and biomechanical perspective, QuadLock™ addresses a long-standing challenge in ACL reconstruction: maintaining graft tension and minimizing cyclic displacement under repeated loading. In high-demand biomechanical testing, QuadLock demonstrated less than 0.5 mm of cyclic displacement, representing a greater than 500% improvement over conventional fixation approaches such as cortical buttons and interference screws, which typically exhibit 3–6 mm displacement. The system also achieved a pullout strength exceeding 1,000 newtons, combining high fixation strength with minimal motion. These characteristics are critical during early postoperative rehabilitation, when repetitive loading can compromise graft integrity and joint stability.
Regulatory Significance
The FDA’s 510(k) clearance confirms that QuadLock™ is substantially equivalent to legally marketed predicate devices, validating its safety and performance for clinical use in ACL reconstruction. For regulatory and quality professionals, this clearance reflects successful navigation of FDA medical device requirements, including design controls, biomechanical validation, and risk management under a compliant quality management system (QMS). The decision allows ABANZA to proceed with U.S. commercialization while reinforcing the importance of robust preclinical evidence in securing regulatory approval for orthopedic fixation devices.
Business Significance
Advertisement
Commercially, the clearance strengthens ABANZA’s U.S. market roadmap and supports its broader platform strategy in soft-tissue repair and sports medicine. ACL reconstruction remains one of the most frequently performed orthopedic procedures, driven by sports injuries and an increasingly active patient population. By offering adjustability, surgeon control, and reproducible fixation, QuadLock positions ABANZA to compete in a crowded but innovation-driven segment of the orthopedic device market. The approval also enhances the company’s ability to engage hospital systems, ambulatory surgery centers, and surgeon innovators seeking next-generation fixation solutions.
Patients’ Significance
For patients, particularly athletes and active individuals undergoing ACL reconstruction, QuadLock™ has the potential to improve early joint stability and support functional recovery. Stable fixation during the critical early healing phase is closely linked to successful graft incorporation and reduced risk of re-injury. By minimizing loss of tension under cyclic loading, the device may contribute to more predictable rehabilitation outcomes, potentially shortening recovery timelines and improving confidence in return-to-activity decisions.
Policy Significance
At a policy level, the clearance underscores the FDA’s role in supporting incremental yet meaningful innovation in orthopedic devices that address evolving patient needs. As ACL injuries rise across diverse age groups, regulators and healthcare systems increasingly emphasize devices that demonstrate measurable biomechanical improvements and safety performance. QuadLock’s clearance highlights how evidence-based design and regulatory compliance can bring advanced surgical tools to market without compromising patient safety.
The FDA 510(k) clearance of ABANZA’s QuadLock™ Fixation System represents a notable advancement in ACL reconstruction technology, combining biomechanical innovation with regulatory rigor. By delivering adjustable, stable fixation under demanding conditions, QuadLock addresses key clinical challenges faced by orthopedic surgeons and patients alike. For the cGxP.wire audience, this milestone illustrates how MedTech innovation, supported by compliant development and validation practices, continues to enhance surgical outcomes within regulated healthcare environments.
Source: ABANZA press release
